Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Lucira Health, Inc. (LHDX)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
1.2700-0.0700 (-5.22%)
At close: 04:00PM EDT
Advertisement

Lucira Health, Inc.

1412 62nd Street
EmeryVille, CA 94608
United States
510 350 8071
https://www.lucirahealth.com

Sector(s)Healthcare
IndustryMedical Devices
Full Time Employees219

Key Executives

NameTitlePayExercisedYear Born
Mr. Erik T. EngelsonPres, CEO & Director1.05MN/A1960
Dr. Debkishore Mitra Ph.D.CTO & DirectorN/AN/A1987
Mr. Kevin Walter CollinsChief Revenue Officer740.75kN/A1977
Mr. Ghazi KashmolahChief Quality Officer & Exec. VP of Regulatory Affairs603.47kN/A1961
Mr. Daniel V. GeorgeCFO & TreasurerN/AN/A1970
Mr. Tony AllenChief Operations OfficerN/AN/A1963
Greg ChodaczekInvestor RelationsN/AN/AN/A
Dr. Nadine Greiner Ph.D.Chief HR OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lucira Health, Inc., a medical technology company, focuses on the development and commercialization of infectious disease test kits. It develops a testing platform that produces molecular testing services. The company offers LUCIRA COVID-19 All-In-One Test Kit, a COVID-19 test kit; and develops influenza A and B viruses test kits. It has a patent license agreement with Eiken Chemical Co., Ltd.; technical services agreement with Jabil, Inc.; and manufacturing services agreement with Jabil MSA. The company was formerly known as DiAssess Inc. and changed its name to Lucira Health, Inc. in January 2020. Lucira Health, Inc. was incorporated in 2013 and is headquartered in Emeryville, California.

Corporate Governance

Lucira Health, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 8. The pillar scores are Audit: 10; Board: 7; Shareholder Rights: 8; Compensation: 8.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement